Vanguard Capital Management’s Lipocine LPCN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$508K Hold
230,823
– – ﹤0.01% 3679
2026
Q2
$591K Buy
230,823
+30,155
+15% +$72.5K ﹤0.01% 3688
2026
Q1
$1.6M Buy
+200,668
New +$1.75M ﹤0.01% 3434

Other funds holding LPCN

Vanguard Capital Management's LPCN Position: Q3 2026 in Review

Vanguard Capital Management held its Lipocine (LPCN) position steady in Q3 2026 at 230,823 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

Vanguard Capital Management first reported a position in LPCN in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.6M in Q1 2026. 24 funds tracked by Wall St. Rank hold LPCN as of Q3 2026.

  • Vanguard Capital Management held 230,823 shares of Lipocine worth $508K as of Q3 2026.
  • Vanguard Capital Management left its Lipocine share count unchanged in Q3 2026.
  • Lipocine made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3679 holding.
  • Vanguard Capital Management first reported a position in Lipocine in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Lipocine position peaked at $1.6M in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Lipocine as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.